Invesaro

Stocks Comparison

Myriad Genetics vs Neogen: revenue, profit, margins and growth compared

Myriad Genetics brought in $824.5M of revenue in fiscal 2025, Neogen $870.4M in fiscal 2026. Revenue changed by -1.6% at Myriad Genetics and -2.7% at Neogen on the year before, so Myriad Genetics grew faster. Myriad Genetics kept -44.4% of its revenue as net profit, Neogen -0.9%.

Side by side, latest fiscal year

MYGNNEOG
Fiscal year endedFY2025 (December 31, 2025)FY2026 (May 31, 2026)
Revenue$824.5M$870.4M
Revenue growth-1.6%-2.7%
Net income-$365.9M-$7.9M
Net margin-44.4%-0.9%
Free cash flown/a$31.9M
Free cash flow marginn/a3.7%
Earnings per share (diluted)-$3.95-$0.04
Cash$149.6M$185.5M
Debt$119.9M$793.7M
Price to earningsn/an/a
Market value$398.9M$3B
Dividend yieldn/an/a
Rank by revenue in sector#159 of 523 · Health care#156 of 523 · Health care

Over the years

Revenue
MYGN FY2019: $851.1MMYGN FY2020: $638.6MMYGN FY2020: $557.1MMYGN FY2021: $690.6MMYGN FY2022: $678.4MMYGN FY2023: $753.2MMYGN FY2024: $837.6MMYGN FY2025: $824.5MNEOG FY2019: $414.2MNEOG FY2020: $418.2MNEOG FY2021: $468.5MNEOG FY2022: $527.2MNEOG FY2023: $822.4MNEOG FY2024: $924.2MNEOG FY2025: $894.7MNEOG FY2026: $870.4MFY19FY20FY21FY22FY23FY24FY25FY26
MYGN $824.5MNEOG $870.4M
Net income
MYGN FY2019: $4.6MMYGN FY2020: -$199.5MMYGN FY2020: -$223.6MMYGN FY2021: -$27.2MMYGN FY2022: -$112MMYGN FY2023: -$263.3MMYGN FY2024: -$127.3MMYGN FY2025: -$365.9MNEOG FY2019: $60.2MNEOG FY2020: $59.5MNEOG FY2021: $60.9MNEOG FY2022: $48.3MNEOG FY2023: -$22.9MNEOG FY2024: -$9.4MNEOG FY2025: -$1.1BNEOG FY2026: -$7.9MFY19FY20FY21FY22FY23FY24FY25FY26
MYGN -$365.9MNEOG -$7.9M
Net margin
MYGN FY2019: 0.5%MYGN FY2020: -31.2%MYGN FY2020: -40.1%MYGN FY2021: -3.9%MYGN FY2022: -16.5%MYGN FY2023: -35.0%MYGN FY2024: -15.2%MYGN FY2025: -44.4%NEOG FY2019: 14.5%NEOG FY2020: 14.2%NEOG FY2021: 13.0%NEOG FY2022: 9.2%NEOG FY2023: -2.8%NEOG FY2024: -1.0%NEOG FY2025: -122.1%NEOG FY2026: -0.9%FY19FY20FY21FY22FY23FY24FY25FY26
MYGN -44.4%NEOG -0.9%
Revenue growth
MYGN FY2020: -25.0%MYGN FY2020: -12.8%MYGN FY2021: +24.0%MYGN FY2022: -1.8%MYGN FY2023: +11.0%MYGN FY2024: +11.2%MYGN FY2025: -1.6%NEOG FY2020: +1.0%NEOG FY2021: +12.0%NEOG FY2022: +12.5%NEOG FY2023: +56.0%NEOG FY2024: +12.4%NEOG FY2025: -3.2%NEOG FY2026: -2.7%FY20FY21FY22FY23FY24FY25FY26
MYGN -1.6%NEOG -2.7%
Free cash flow
MYGN FY2019: $75.1MMYGN FY2020: $50.5MMYGN FY2021: $600KMYGN FY2022: -$151.6MNEOG FY2019: $49.2MNEOG FY2020: $61.8MNEOG FY2021: $54.4MNEOG FY2022: $43.6MNEOG FY2023: -$24.7MNEOG FY2024: -$76.1MNEOG FY2025: -$46.4MNEOG FY2026: $31.9MFY19FY20FY21FY22FY23FY24FY25FY26
MYGN -$151.6MNEOG $31.9M

Fiscal years as each company reports them; the two may end in different months.

Questions about Myriad Genetics and Neogen

Which is bigger by revenue, Myriad Genetics or Neogen?

Neogen is bigger by revenue: $870.4M in fiscal 2026, against $824.5M for Myriad Genetics in fiscal 2025.

Which keeps more of its revenue as profit, Myriad Genetics or Neogen?

Myriad Genetics had a net margin of -44.4% in fiscal 2025; Neogen had -0.9% in fiscal 2026.

Which grew revenue faster, Myriad Genetics or Neogen?

In their latest fiscal years revenue changed by -1.6% at Myriad Genetics and -2.7% at Neogen.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies